Defence Therapeutics Inc. (DTC.CN)
| Previous Close | 7.60 |
| Open | 7.89 |
| Bid | 7.55 x N/A |
| Ask | 7.83 x N/A |
| Day's Range | 7.60 - 7.89 |
| 52 Week Range | 2.56 - 8.15 |
| Volume | 20,100 |
| Avg. Volume | 18,984 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.09 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Newsfile
Defence Therapeutics Success in Testing Its COVID-19 AccuVAC-PT001 Vaccine in a Non-Rodent Model
Vancouver, British Columbia--(Newsfile Corp. - September 14, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a biotechnology company working on cancer therapeutics and infectious disease vaccines, is pleased to announce the completion of a non-GLP study on rabbits demonstrating a potent humoral response with titer reaching 1:43 000 000 per average without any signs of toxicity. Defence has previously developed and tested its AccuVAC-PT001 v
- Newsfile
Defence Therapeutics Files Acid-Based Hydrogels USA Provisional Patent Application
Vancouver, British Columbia--(Newsfile Corp. - August 31, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a biotechnology company working on ADC therapeutics for cancer targeting with its AccumTM technology and cancer vaccine therapeutics and infectious disease vaccines is pleased to announce the expansion of its patent portfolio through the filing of its AccumTM technology-based USA Provisional Patent Application named "Steroid Acid-Based
- Newsfile
Defence Therapeutics Selects the Best Eight Accum(TM) Variants to Optimize Its ADC Therapeutic
Vancouver, British Columbia--(Newsfile Corp. - August 18, 2021) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), is pleased to announce, that after a detailed and rigorous selection process, very strong and promising results of its bests AccumTM variants has been identified. Defence's has tested 43 AccumTM variants conjugated to T-DM1 with a low conjugation ratio (1-4 AccumTM per T-DM1) in order to select the best ones to pursue our selection of the ...
